Clinical Trial Update: Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203) [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update on ALTER0203 evaluating Anlotinib in soft tissue sarcoma across Phase 2 and Phase 3, with the current status not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Soft Tissue Sarcoma | Phase 2, Phase 3 | Status: UNKNOWN